Heparin resistance is a complex medical challenge that occurs when patients require unusually high doses of a blood-thinning medication called heparin to prevent dangerous blood clots. This condition can complicate treatment in intensive care units and during major surgeries, leaving doctors searching for alternative approaches to protect patients from life-threatening complications.

Understanding Heparin Resistance

When doctors need to prevent blood clots quickly in critically ill patients, they often turn to unfractionated heparin, a medication that has been used for decades. This drug works rapidly and can be reversed just as quickly when needed, making it especially valuable during surgeries involving the heart or when patients are connected to life-support machines. However, in some patients, normal doses of heparin simply don’t work as expected, a phenomenon known as heparin resistance.^[1]

The term heparin resistance refers to the failure of appropriate doses of unfractionated heparin to achieve the desired level of anticoagulation, meaning the blood doesn’t thin as much as it should. Unfortunately, despite numerous medical reports over the years, there is no universal agreement on what exactly constitutes an “appropriate dose” or what the target level of anticoagulation should be. This lack of consensus makes the condition somewhat difficult to define and study.^[2]

Different medical institutions use different standards. Some define heparin resistance as requiring more than 35,000 units of heparin per day to maintain the desired blood-thinning effect, while others use a weight-based definition requiring more than 20 units per kilogram of body weight per hour. In patients undergoing procedures requiring cardiopulmonary bypass (a heart-lung machine used during cardiac surgery), the definition becomes more specific: needing more than 500 units per kilogram of heparin to achieve a particular blood test result.^[1][4]

How Common Is This Condition?

The frequency of heparin resistance varies considerably depending on the patient population and the specific medical setting. In patients undergoing heart surgery with cardiopulmonary bypass, reported rates range from 4% to 26%. This wide variation depends on several factors, including how much heparin is given initially and what target blood test value doctors are aiming to achieve before starting the bypass procedure.^[4]

During the coronavirus disease 2019 pandemic, doctors noticed heparin resistance occurring more frequently in critically ill patients. This observation shouldn’t have been entirely surprising, since heparin resistance is generally more common in intensive care unit patients, especially those who are more severely ill with higher levels of inflammation throughout their bodies.^[1][12]

What Causes Heparin Resistance?

To understand why heparin resistance occurs, it helps to know how heparin normally works. Heparin doesn’t thin the blood directly. Instead, it binds to and activates a natural protein in the blood called antithrombin, formerly known as antithrombin III. Once activated by heparin, antithrombin can then block several clotting factors in the blood, particularly factor Xa and factor IIa (also called thrombin), thereby preventing dangerous blood clots from forming.^[4][1]

Heparin is actually a mixture of molecules called glycosaminoglycans purified from porcine intestine or bovine lung. Only about one-third of heparin molecules contain a special structure called a pentasaccharide sequence that allows them to bind to antithrombin. This inherent variability is one reason why heparin’s anticoagulant effect differs so much from person to person.^[1]

The most common cause of true heparin resistance is antithrombin deficiency. Since heparin relies on antithrombin to work, having insufficient amounts of this protein means heparin cannot perform its job effectively, no matter how much is given. Antithrombin levels can drop for many reasons, including liver disease, active blood clot formation, disseminated intravascular coagulation (a serious condition where blood clots form throughout the body’s small vessels), or after major surgery.^[4][2]

Another important cause involves increased clearance of heparin from the bloodstream. When patients are critically ill, their bodies may eliminate heparin more quickly than usual, reducing its concentration and effectiveness. Additionally, during severe illness and inflammation, the body produces increased amounts of certain proteins that can bind to heparin and prevent it from doing its work. These heparin-binding proteins, including platelet factor 4 and other acute-phase reactants, essentially trap heparin molecules, making them unavailable to activate antithrombin.^[4][12]

Risk Factors for Developing Heparin Resistance

Several medical conditions and situations increase the likelihood of developing heparin resistance. Patients in intensive care units face higher risk, particularly those with severe multi-organ failure or those requiring extracorporeal circuits such as extracorporeal membrane oxygenation, a life-support machine that does the work of the heart and lungs.^[1]

People undergoing major cardiac surgery, especially procedures requiring cardiopulmonary bypass, are at increased risk. These operations create significant stress on the body and often trigger inflammatory responses that can lead to heparin resistance. The risk increases with the complexity and duration of the surgical procedure.^[4]

Conditions associated with hypercoagulability, meaning an increased tendency for blood to clot, also raise the risk. These include thrombocytosis (abnormally high platelet counts), antiphospholipid antibody syndromes (immune system disorders that increase clotting risk), and active venous thromboembolism (blood clots in veins). Patients who have recently received andexanet alfa, a medication used to reverse direct oral anticoagulants, may also experience heparin resistance.^[2]

Acute infections and severe inflammatory conditions, including COVID-19, substantially increase the risk. The intense inflammatory response these conditions trigger leads to increased production of heparin-binding proteins and may also cause antithrombin deficiency, creating a perfect storm for heparin resistance.^[1][12]

Symptoms and Clinical Manifestations

Heparin resistance itself doesn’t cause symptoms that patients can feel or notice. Instead, it manifests as a medical management problem that healthcare providers identify through laboratory testing. The primary concern is that when heparin doesn’t work properly, patients remain at risk for developing dangerous blood clots despite receiving what would normally be adequate treatment.^[2]

Healthcare providers should suspect heparin resistance when usual heparin doses fail to prolong certain blood clotting tests to the desired therapeutic range. These tests include the activated partial thromboplastin time (aPTT) used for patients in regular hospital wards or intensive care units, and the activated clotting time (ACT) used during vascular interventions and heart surgery.^[4][2]

The clinical consequences of unrecognized or untreated heparin resistance can be serious. Patients may develop blood clots despite being on heparin therapy, potentially leading to complications such as deep vein thrombosis, pulmonary embolism, or clotting within medical devices like dialysis catheters or extracorporeal circuits. In some cases, heparin resistance was associated with thrombotic complications in small series of patients during the COVID-19 pandemic.^[1]

Prevention Strategies

Preventing heparin resistance entirely is challenging because many of its underlying causes—such as critical illness, major surgery, or severe infection—cannot be avoided in patients who need these treatments. However, certain strategies can help minimize risk or allow for early detection and intervention.^[1]

Using weight-based dosing of heparin rather than fixed doses represents an important preventive approach. This ensures that patients receive amounts of heparin appropriate for their body size, reducing the likelihood that inadequate dosing will be mistaken for true resistance. Early reports of heparin resistance used daily doses that didn’t account for body weight, which may have contributed to apparent resistance in larger patients.^[2]

In patients known to have conditions that predispose them to heparin resistance, such as known antithrombin deficiency or recent major surgery, healthcare providers can plan ahead. This might include having alternative anticoagulants available or planning for more intensive monitoring of anticoagulation levels. Awareness of the problem allows for quicker recognition and response.^[4]

Choosing appropriate monitoring tests is also important. While traditional clotting tests like aPTT are widely available and familiar, they can be affected by many factors beyond heparin levels, especially in critically ill patients with inflammation. Using anti-Xa testing when available provides a more direct and accurate assessment of heparin’s anticoagulant effect, allowing for better dose adjustments and potentially preventing the development of apparent resistance due to misleading test results.^[2]

How the Body Changes in Heparin Resistance

The pathophysiology of heparin resistance—the changes in normal body function that lead to this condition—involves several interconnected mechanisms. Understanding these changes helps explain why some patients respond poorly to heparin and guides treatment decisions.^[4]

In normal circumstances, heparin molecules circulate in the blood and encounter antithrombin molecules. When a heparin molecule with the correct pentasaccharide sequence binds to antithrombin, it causes a change in antithrombin’s shape that makes it much more effective at grabbing and inactivating clotting factors, particularly factor Xa and thrombin. This accelerates the natural anticoagulant process by about 1,000-fold. Once the clotting factor is neutralized, heparin releases from the complex and can activate another antithrombin molecule.^[1]

In patients with antithrombin deficiency, this entire process breaks down. Without sufficient antithrombin present, heparin has nothing to activate, no matter how much is given. Antithrombin deficiency can be congenital (inherited) or acquired. Acquired deficiency is more common in hospitalized patients and occurs through several mechanisms: consumption during active clot formation, decreased production by a diseased liver, loss through damaged kidneys in nephrotic syndrome, or dilution after receiving large volumes of intravenous fluids or blood transfusions during surgery or critical illness.^[4]

When inflammation is present, the body increases production of various proteins as part of its defense response. Some of these so-called acute-phase proteins have a strong affinity for binding heparin. When heparin molecules become bound to these proteins, they’re no longer available to bind to and activate antithrombin. Essentially, these proteins act as decoys, soaking up heparin molecules and preventing them from doing their intended job. This mechanism explains why heparin resistance is more common in patients with severe infections, major trauma, or inflammatory conditions.^[4][12]

Additionally, heparin can bind nonspecifically to many other components in blood, including macrophages (immune cells), platelets, and various plasma proteins. In critically ill patients with high levels of these components, more heparin gets trapped in these non-productive interactions. Some heparin may also remain unbound in the plasma but still not reach therapeutic levels at the sites where it’s needed. These factors contribute to increased heparin clearance from the circulation, effectively lowering its concentration and reducing its anticoagulant effect.^[4]

There’s also a phenomenon called pseudo heparin resistance, which isn’t true physiological resistance at all. This occurs specifically when heparin effectiveness is being monitored using aPTT testing. High levels of certain clotting factors, particularly factor VIII and fibrinogen, can artificially shorten the aPTT, making it appear that heparin isn’t working when it actually is. This is particularly relevant because factor VIII and fibrinogen are both acute-phase reactants that increase during inflammation. In these cases, the heparin is working fine, but the test results are misleading.^[12]